About Us
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
About
Explore Content
For Authors
Alert & RSS Feed
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Fei Ma is the chief physician & director of Internal Therapy Center of Cancer Hospital, principal investigator of State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences. He has long been dedicated to basic, clinical and translational research in oncology, focusing on interdisciplinary studies. In the past 5 years, he has published more than 50 peer-reviewed papers as first/corresponding author, especially in Lancet Oncology, Journal of Clinical Oncology and Nature Communication. He also created a new model of "all-round and whole-cycle" management for breast cancer patients, published related guidelines, conducted clinical research on tumor cardiology & neurology, and promoted the development of tumor co-morbidity management and new interdisciplinary disciplines. He is also the founder of Chinese Cancer Innovation (CCI) consortium, the Asia Pacific leader of International Metronomic Chemotherapy Academy, chairman of Boao Cancer Innovation Institute, chairman of Biosimilar Collaborate Team (BCT) & Cancer Health Management Committee, Cancer Foundation of China and vice chairman in Committee of Cardio-Oncology, Chinese Anti-cancer Association (CACA).
Wenbin Li
Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Wenbin Li is the Director of Cancer Center and Neuro-Oncology Department, Beijing Tiantan Hospital; Director of Department of Oncology, Capital Medical University (CMU); Vice Chairman of Drug Clinical Research Specialty Committee, President of FCN-159-002 SMC; Committee member, Asian Oncology Society (AOS) Academic Committee; Standing Committee Member and General Secretary of Glioma Specialty Committee, Chinese Medical Doctor Association (CMDA); Director of Department of Journal Publishing, Chinese Anti-Cancer Association (CACA); Chief Editor of Committee of neuro-oncology channel, Chinese medical reference newspaper. He is also Honorary Research Fellow at University of South Florida; Foreign Academician of the Royal Society of Medicine. He is very skilled at chemotherapy of intracranial malignant tumors and studies on the drug clinical trials. He is in charge of two novel drugs in phase I clinical trial, which belong to National Science and Technology Major Project for “Significant New Drugs Development” during the 13th Five-year Plan period, and the project has completed 20 phase I-IV clinical trials.
Shun Lu
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
Shun Lu served as the leading PI for more than 20 multi-center Phase III oncology clinical trials and participated as the key contributor for more than 50 global and regional clinical trials as well. He has authored more than 200 peer-reviewed articles, many of which has published at JCO, Lancet Respiratory Medicine, Annuals of Oncology, Clinical Cancer Research, Chest and JTO etc. Prof. Lu is the advisory board member for Center for Drug Evaluation at NMPA. He is also the chair of Chinese Lung Cancer Association and executive director of CSCO.
Haili Qian
Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Haili Qian received his Ph.D. degree from Chinese Academy of Medical Sciences and Peking Union Medical College in 2005. His research interests focusing on the understanding of cancer etiology and signaling pathway regulation as well as how these networks potentially contribute to the cancer therapy. He is the member of Youth Council of China Anti-Cancer Association. He also services as an associate editor for the journals of Military Medical Research and Frontiers of Oncology.
Yu Rao
Tsinghua University, Beijing, China
Yu Rao obtained his Ph.D. degree from University of Georgia. He then carried out post doctorial research work at Sloan-kettering Cancer Center. He joined School of Medicine in Tsinghua University in January of 2010. His research interests are focused on developing novel small molecule-based therapeutics for drug-resistant cancer and infectious disease treatments. His laboratory utilizes the expertise in the fields of medicinal chemistry, chemical biology, and synthetic chemistry to develop lead compounds for important drug targets and explore new potential therapeutic targets. In recent years, his laboratory is mainly working on protein degradation/PROTAC method development and application in related disease treatments.
Zhuo Yu
Beijing Tsinghua Changgung Hospital, Beijing, China
Zhuo Yu received his M.D. degree from Pekin Union Medical Collegeis. He is the Attending Physician and Associate Professor of Department of Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medical, Tsinghua University, Beijing. He’s also the member of the Hepato-Bilio-Pancreatology Professional Committee of Beijing Anti-Cancer Association, standing committee member of the Lung Cancer Committee and member of the Palliative Medicine Committee of Beijing Association of Oncology, member of the Chemotherapeutical-Quality-Control Committee of Beijing Cancer Quality Control and Improvement Center, Editorial board member of Electronic Journal of Liver Tumor. He engaged in digestive tract malignancies including Hepato-Bilio-Pancreatic cancers, esophageal and gastric cancers, colorectal malignant tumors, et al. His main research areas are related to cancer prevention and clinical treatment, as well as side effects alleviation, nutritional support, and standardized pain management.
Jianyang Zeng
Tsinghua University, Beijing, China
Jianyang Zeng is an Associate Professor with Tenure and a doctoral advisor at the Institute for Interdisciplinary Information Sciences, Tsinghua University. He received his Ph.D. in Computer Science from Duke University in 2011. He has over 70 publications, including those on Nature Machine Intelligence, Nature Communications, PNAS, Cell Systems, and Nucleic Acids Research. He received multiple awards for his research, including ESI Highly Cited Paper, Wuwenjun AI Science and Technology Award Third Prize for the Natural Science track 2019, China’s Top Ten Bioinformatics Advances of 2019 and 2020, China’s Top 10 Bioinformatics Algorithms and Instruments, World Artificial Intelligence Conference Youth Outstanding Paper Award, and ICIBM Best Paper Award 2019. He is an Associate Editor of IEEE/ACM Transactions on Computational Biology and Bioinformatics and was on the program committee of top computational biology conferences such as ISMB and RECOMB.
Jianjun Jay Zhang
The University of Texas, MD Anderson Cancer Center, Houston, USA
Jianjun Jay Zhang is an Associate Professor in the Dept. Thoracic/Head and Neck Medical Oncology; Dept. Genomic Medicine, The University of Texas, MD Anderson Cancer Center. His research interests include cancer genomics, cancer immunology, cancer evolution, immunotherapy etc. Prof. Zhang has published over 100 peer-reviewed articles in Nature, Science, Lancent Oncology, JCO, Annals of Oncology, JTO, Nature Communications etc. in the past 5 years.
Meng Chen
Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
Meng Chen is the Deputy Director, National Cancer Data Center, National Cancer Center / Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College. She received her Ph.D. degrees from the University of Texas Health Science Center at Houston and MD Anderson Cancer Center. She has been engaged in identifying biomarkers for cancer risk prediction, diagnosis, and prognosis, as well as real world study using molecular epidemiology and big data tools.
Mengchun Gong
Institute of Health Management, Southern Medical University, Guangzhou, China
Mengchun Gong graduated from Peking Union Medical College with an M.D. degree, and entered Peking Union Medical College Hospital in 2014, after which time he worked in University of California, San Francisco as a visiting scholar. He joined the area of applied medical informatics since 2015 and now works as the Distinguished Professor in the Institute of Health Management, Southern Medical University, China. He is actively engaged with international academic societies and holds the positions including the Diagnostic Science Committee member of IRDiRC , Director of the Management Board of SNOMED International, and the member of the executive committee of the Chinese Association of Bioinformatics. He took charge of the National Rare Diseases Registry System of China as the executive director from 2016 to 2019 and has been a pioneer in rare disease research and patient advocacy in China. His research focus covers medical terminology/ontology, rare diseases research and health technology assessment (HTA) for orphan medicinal products.
Yingjie Tian
School of Economics and Management, University of Chinese Academy of Sciences; Research Center of Fictitious Economy and Data Science, Chinese Academy of Sciences, Beijing, China
Yingjie Tian has published 5 Chinese and English Monographs and more than 50 papers in international academic journals and international conferences in recent 5 years. Academic achievements have been widely cited and evaluated by well-known scholars at home and abroad. He has participated in more than 10 general projects, key projects, innovation groups, major international cooperation, major special projects of a certain ministry, and knowledge innovation projects of the Chinese Academy of Sciences.
Xuntao Yin
Guangzhou Women and Children's Medical Center, Guangzhou, China
Xuntao Yin received the Ph.D. degree at Shandong University and was co-trained at McGill University in Canada in 2012. He later went to the United States as a visiting scholar at the Department of Radiology in Mayo Clinic in 2016. In the past 5 years, He has published more than 50 SCI papers. He has participated in several national or provincial research projects with a total 4 million dollars funds. He has written 7 monographs (two as chief editor) and obtained 4 software copyrights.
